# Laviana Pharmatech Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/laviana-pharmatech-co

- Industry: Pharmaceuticals
- Headquarters: China
- Website: www.lavianacorp.com
- Total disclosed funding: $112M
- Latest round: Series C (Oct 13, 2021)
- Investors on record: 16

## About

Founded in 2003, and based in Jiangsu, China, Laviana Pharmatech Co., Ltd. operates as a medical technology company that focuses on offering outsourcing services for the pharmaceutical industry. It has one R&D centre in Tianjin, a GMP production base in Cangzhou, a pharmaceutical intermediates commercial production base in Jiangsu, and 3 business centres including Beijing, and Shanghai. The company's R&D team members used to work for Pfizer, BMS, DuPont, Pharma, GSK, and other international pharmaceutical and biotechnology companies.

It provides small molecule innovative drug development and manufacturing services. The services include process research, process development, process optimization, pilot scale production, commercial-scale production of raw material, GMP starting material, and intermediates. The service covers pre-clinical development, clinical trial materials, and commercialized products.  It also provides CMC services for IND and NDA submissions for an investigational drug.

Laviana Pharmatech Co., Ltd. will use the series C+ funding for establishing R&D, and production bases of active pharmaceutical ingredients in Lujiang county.

## Funding rounds

- Series C, Oct 13, 2021, $78M — Yingke Private Equity, HY Capital, Shiyue Capital, Pingtan Shenghong Investment Management, Space Investment Partners, HRVC Capital, Yinglian Capital, Yueshi Investment
- Series B, Aug 26, 2019, $14M — V-Capital, China Merchants Wealth Asset Management
- Series B, Jan 2, 2018, $15M — ABC Capital, LYFE Capital, Crystal Pharmatech, HY Capital
- Series A, Mar 1, 2014, $4.9M — Lotus Lake Capital, Shuimu Qinghua Capital, Zhongnongkechuang investment Co.,Ltd.

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A
- Shuimu Qinghua Capital (https://capitalatlas.ai/funds/shuimu-qinghua-capital) — Series A
- Zhongnongkechuang investment Co.,Ltd. — Series A
- ABC Capital (https://capitalatlas.ai/funds/abc-capital) — Series B
- LYFE Capital — Series B
- Crystal Pharmatech — Series B
- HY Capital (https://capitalatlas.ai/funds/hy-capital) — Series B, Series C
- V-Capital (https://capitalatlas.ai/funds/v-capital) — Series B
- China Merchants Wealth Asset Management — Series B
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series C
- Shiyue Capital — Series C
- Pingtan Shenghong Investment Management — Series C
- Space Investment Partners — Series C
- HRVC Capital (https://capitalatlas.ai/funds/hrvc-capital) — Series C
- Yinglian Capital — Series C
- Yueshi Investment — Series C